(NASDAQ: MDXG) Mimedx Group's forecast annual revenue growth rate of 6.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 99.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Mimedx Group's revenue in 2025 is $393,442,000.On average, 7 Wall Street analysts forecast MDXG's revenue for 2025 to be $61,555,700,345, with the lowest MDXG revenue forecast at $58,056,046,328, and the highest MDXG revenue forecast at $64,006,791,077. On average, 7 Wall Street analysts forecast MDXG's revenue for 2026 to be $62,854,556,280, with the lowest MDXG revenue forecast at $54,862,963,780, and the highest MDXG revenue forecast at $72,296,068,916.
In 2027, MDXG is forecast to generate $70,868,364,103 in revenue, with the lowest revenue forecast at $62,410,249,803 and the highest revenue forecast at $81,813,113,653.